← Zhejiang Yatai Pharmaceutical overview

Zhejiang Yatai Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Zhejiang Yatai Pharmaceutical Co Ltd (002370.CS)

Q3 2026
▲2

Buyback and pipeline progress offset by weak reported profit

  • Buyback plan and first tranche completed The chairman proposed a 10-20 million yuan buyback for equity incentives, and the company then completed a first tranche of about 3.34 million shares for roughly 20 million yuan. Buying its own stock signals confidence and supports the share price.

    This is the main capital action driving the stock and shows management's confidence.

  • Spironolactone tablets pass consistency review Yatai's spironolactone tablets passed China's generic drug quality and efficacy consistency evaluation. This enriches its product pipeline and makes the drug more competitive in hospital procurement, supporting future sales.

    It is a concrete regulatory win that improves the product pipeline and competitiveness.

  • H1 underlying profit turns positive but reported net loss First-half revenue rose 3.6% to 158 million yuan, and non-recurring net profit swung to a 1.4 million yuan gain from a big loss, helped by lower financial expenses and more high-margin non-antibiotic products. But reported net profit was a 440,000 yuan loss, down 100.4% year on year.

    It shows the core business improving while the headline reported profit still disappoints, a key counterweight.

August 2026
▲2

Buyback and pipeline progress offset by weak reported profit

  • Buyback plan and first tranche completed The chairman proposed a 10-20 million yuan buyback for equity incentives, and the company then completed a first tranche of about 3.34 million shares for roughly 20 million yuan. Buying its own stock signals confidence and supports the share price.

    This is the main capital action driving the stock and shows management's confidence.

  • Spironolactone tablets pass consistency review Yatai's spironolactone tablets passed China's generic drug quality and efficacy consistency evaluation. This enriches its product pipeline and makes the drug more competitive in hospital procurement, supporting future sales.

    It is a concrete regulatory win that improves the product pipeline and competitiveness.

  • H1 underlying profit turns positive but reported net loss First-half revenue rose 3.6% to 158 million yuan, and non-recurring net profit swung to a 1.4 million yuan gain from a big loss, helped by lower financial expenses and more high-margin non-antibiotic products. But reported net profit was a 440,000 yuan loss, down 100.4% year on year.

    It shows the core business improving while the headline reported profit still disappoints, a key counterweight.

Latest
▲2

Buyback and pipeline progress offset by weak reported profit

  • Buyback plan and first tranche completed The chairman proposed a 10-20 million yuan buyback for equity incentives, and the company then completed a first tranche of about 3.34 million shares for roughly 20 million yuan. Buying its own stock signals confidence and supports the share price.

    This is the main capital action driving the stock and shows management's confidence.

  • Spironolactone tablets pass consistency review Yatai's spironolactone tablets passed China's generic drug quality and efficacy consistency evaluation. This enriches its product pipeline and makes the drug more competitive in hospital procurement, supporting future sales.

    It is a concrete regulatory win that improves the product pipeline and competitiveness.

  • H1 underlying profit turns positive but reported net loss First-half revenue rose 3.6% to 158 million yuan, and non-recurring net profit swung to a 1.4 million yuan gain from a big loss, helped by lower financial expenses and more high-margin non-antibiotic products. But reported net profit was a 440,000 yuan loss, down 100.4% year on year.

    It shows the core business improving while the headline reported profit still disappoints, a key counterweight.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.